Free Trial
Laura Prendergast

Laura Prendergast Analyst Performance

Managing Director- Biotech Equity Research at Stifel Nicolaus

Laura Prendergast is a stock analyst at Stifel Nicolaus in the medical sector, covering 6 publicly traded companies. Over the past year, Laura Prendergast has issued 7 stock ratings, including buy and hold recommendations. While full access to Laura Prendergast's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Laura Prendergast's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
7 Last 0 Years
Buy Recommendations
71.43% 5 Buy Ratings
Companies Covered
6 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy71.4%5 ratings
Hold28.6%2 ratings
Sell0.0%0 ratings

Out of 7 total stock ratings issued by Laura Prendergast at Stifel Nicolaus, the majority (71.4%) have been Buy recommendations, followed by 28.6% Hold.

Best & Worst Calls

This analyst does not have any ratings with enough history to determine best and worst calls.

Exchange Coverage

ExchangePercentageCount
NASDAQ
100.0% of companies on NASDAQ
6 companies

Laura Prendergast, an analyst at Stifel Nicolaus, currently covers 6 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
6 companies
100.0%

Laura Prendergast of Stifel Nicolaus specializes in stock coverage within the Medical sector.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
6 companies
100.0%

Laura Prendergast's Ratings History at Stifel Nicolaus

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Nuvalent, Inc. stock logo
NUVL
Nuvalent
10/16/2025Initiated Coverage$92.75$115.00Buy
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
10/15/2025Initiated Coverage$4.15$8.00Buy
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
10/15/2025Initiated Coverage$49.56$85.00Buy
Erasca, Inc. stock logo
ERAS
Erasca
10/15/2025Initiated Coverage$2.49$4.00Buy
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
10/15/2025Initiated Coverage$16.57$16.00Hold
Erasca, Inc. stock logo
ERAS
Erasca
3/26/2025Initiated Coverage$1.48$5.00Outperform
Third Harmonic Bio, Inc. stock logo
THRD
Third Harmonic Bio
2/11/2025Reiterated Rating$4.65Market Perform